Post-marketing Clinical Study of Alteplase for Acute Ischemic Stroke （Japan Alteplase Clinical Trial Ⅱ：J-ACT Ⅱ）
Status:
Completed
Trial end date:
2008-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to confirm the efficacy and safety of intravenously administered
alteplase in patients with acute ischemic stroke based on the rate of recanalization assessed
by magnetic resonance angiography (MRA), the rate of patients with a modified Rankin Scale
(mRS) score of 0-1, and the incidence of symptomatic intracranial hemorrhage (sICH), in
comparison with the data reported in the current literature.
Phase:
Phase 4
Details
Lead Sponsor:
Mitsubishi Tanabe Pharma Corporation
Collaborators:
Kyowa Hakko Kirin Company, Limited Kyowa Kirin Co., Ltd.